Early response patterns on omalizumab predict long‐term outcomes in chronic spontaneous urticaria

Documenti analoghi

• Treatment refractory chronic spontaneous urticaria may benefit from treatment with dupilumab: A case series of eight patients
  di: S. E. B. Feldborg, et al.
  Pubblicazione: (2024)
• Improvements in patient‐reported outcomes with oral roflumilast for psoriasis: Results from a randomized controlled trial (PSORRO)
  di: Mette Gyldenløve, et al.
  Pubblicazione: (2024)
• Drug survival of alitretinoin treatment for chronic hand eczema: A Danish nationwide cohort study
  di: Amalie Thorsti Møller Rønnstad, et al.
  Pubblicazione: (2024)
• Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long‐term use
  di: Alexander Egeberg, et al.
  Pubblicazione: (2024)
• Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries
  di: Maria‐Magdalena Balp, et al.
  Pubblicazione: (2025)